Expertise in
3
conditions

Feng Bi

CN 
Expertise in
3
conditions
CN 

Overview

Feng Bi practices practicing medicine in China.

Mr. Bi is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Stomach Cancer, Liver Cancer, Hepato-Pancreato-Biliary Surgery, and Gastrectomy.

He is actively involved in clinical research, co-authoring 167 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

China
Other Locations
State Key Laboratory Of Biotherapy, Chengdu, China
Changsha, 410013, China
Beijing, 100142, China
Huaxi, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
Enrollment Status: Unknown
Publish Date: December 13, 2021
Intervention Type: Biological
Study Drug: JS001 Anti-PD-1 Antibody
Study Phase: Phase 1/Phase 2
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial
Enrollment Status: Completed
Publish Date: January 09, 2020
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

167 Total Publications

Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.
Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.
Journal: JAMA network open
Published: June 15, 2026

Frequently Asked Questions about Feng Bi

Is Feng Bi a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Feng Bi is classified as an Advanced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Feng Bi participate in research or clinical trials?

Yes. Feng Bi has published 167 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Feng Bi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bi's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile